3. Intangible Assets, Goodwill and Other

9 Months Ended

Sep. 30, 2021

GOODWILL AND OTHER PURCHASED INTANGIBLE ASSETS

Goodwill by segment are as follows (in millions):


	Life Science		Clinical Diagnostics		Total











Balances as of September 30, 2021 and December 31, 2020:
Goodwill	$	277.9	$	349.2	$	627.1
Accumulated impairment losses	(41.8)		(293.4)		(335.2)
Goodwill, net	$	236.1	$	55.8	$	291.9

Information regarding our identifiable purchased intangible assets with definite and indefinite lives is as follows (in millions):


	September 30, 2021
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.37	$	112.3	$	(89.6)	$	22.7
Know how	4.00	173.3		(155.4)		17.9
Developed product technology	13.57	216.1		(113.5)		102.6
Licenses	7.03	65.1		(39.8)		25.3
Tradenames	7.48	6.4		(4.4)		2.0
Covenants not to compete	3.28	4.6		(2.6)		2.0

Other	—	0.1		(0.1)		—
Total definite-lived intangible assets		577.9		(405.4)		172.5
In-process research and development		4.6		—		4.6
Total purchased intangible assets		$	582.5	$	(405.4)	$	177.1


	December 31, 2020
	Weighted-Average Remaining Amortization Period (years)	Purchase Price		Accumulated Amortization		Net Carrying Amount
Customer relationships/lists	5.51	$	116.6	$	(87.2)	$	29.4
Know how	4.75	196.6		(175.4)		21.2
Developed product technology	14.00	218.1		(107.1)		111.0
Licenses	7.73	65.6		(37.4)		28.2
Tradenames	7.82	6.6		(4.2)		2.4
Covenants not to compete	3.87	4.5		(2.0)		2.5

Other	—	0.1		(0.1)		—
Total definite-lived intangible assets		608.1		(413.4)		194.7
In-process research and development		4.8		—		4.8
Total purchased intangible assets		$	612.9	$	(413.4)	$	199.5

Amortization expense related to purchased intangible assets is as follows (in millions):